Skip to Content

EADV 2025: Interim Real-World Data from ADlife on Lebrikizumab in Moderate-to-Severe AD

New interim real-world data from the ADlife study explore the effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis. Early results at weeks 4 and 16 suggest promising clinical outcomes in a comorbid, treatment-experienced population.
Image courtesy of the European Academy of Dermatology and Venereology (EADV).
Image courtesy of the European Academy of Dermatology and Venereology (EADV).

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top